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Abstract
The thesis entitled "Enantioselective Synthesis of Bioactive Molecules using Asymmetric Dihydroxylation, Reduction, Bromination and Oxidations involving C-H and C-N Bonds" is divided into four chapters. 
The title of the thesis clearly highlights two aspects of the synthetic organic chemistry: (i) the achievement of efficient stereospecific synthesis of bioactive molecules (ii) development of transition metal-based catalytic methods for useful organic transformations. Chapter 1 describes the enantioselective synthesis of (R)-Lipoic acid, an anti-HIV and anti-tumor agent and (R)-1-butyryl glycerol, a novel angiogenesis factor, using OsO 4 -catalyzed asymmetric dihydroxylation. Chapter 2 also deals with the application of OsO 4 -catalyzed asymmetric dihydroxylation as a key reaction for the enantioselective synthesis of (S)-Xibenolol, a b-adrenergic blocker for the treatment of hypertension and (R)-Fepradinol, an anti-inflammatory drug. Chapter 3 presents the asymmetric synthesis of (R)-Baclofen, a GABA B receptor agonist using Ru(II)-(S)-BINAP-catalyzed asymmetric hydrogenation and acyclic nucleotides, (S)-2,3-dihydroxypropyl-(9)-adenine via asymmetric dihydroxylation approaches. Chapter 4 comprises the development of catalytic methods for asymmetric dibromination of olefins, peroxidation of alkyl arenes and oxidation of nitroaldols, thus producing chiral dibromides, unsymmetrical peroxides and a-keto acids respectively. 
CHAPTER-I OsO 4 -catalyzed asymmetric dihydroxylation of olefins (AD) is the most practical and potential reaction to yield diols with high degree of stereoselectivity and optical purity. 1 f0 It is insensitive to oxygen, easy to handle and performed in water at room temperature in the presence of derivatives of dihydroquinidine and dihydroquinine ligands. This chapter is divided into two sections and each section represents the application of asymmetric dihydroxylation methodology for the synthesis of bioactive molecules. 



SECTION-I Asymmetric Synthesis of (R)-Lipoic acid, an Anti-HIV and Anti-tumor Agent, via OsO 4 -Catalyzed Asymmetric Dihydroxylation Approach 2 b0 (R)-Lipoic acid (6, 8-dithiooctanoic acid, 7) is the naturally occurring cyclic disulfide compound and found to display an extremely high level of biological activity. Its catalytic oxidative decarboxylation of pyruvate to acetate, plays an important role as a protein bound transacylating cofactor of several multienzymatic dehydrogenases complexes. 3 f0 Their salts have cytoprotective activity and are analgesic and anti-inflammatory drugs as well as agents for the treatment of retroviral infections. 4 f0 This section presents the enantioselective synthesis of (R)-Lipoic acid (7) via asymmetric dihydroxylation approach (Scheme 1). Precursor, octenedioic ester (2) was synthesized in 2 steps from easily available ?-caprolactone. It was subjected to OsO 4 -catalyzed asymmetric dihydroxylation in the presence of (DHQD) 2 -PHAL as a chiral ligand to afford chiral diol 3 in 92% yield and 96%ee. The diol 3 was converted to cyclic sulfate 4 under the standard reaction conditions in 81% overall yield. 5 b Reductive ring opening of 4 by NaBH 4 gave the intermediate 5 in 76% yield. Further, the selective reduction of the b-hydroxyester 5 was achieved using NaBH 4 b in the presence of Et 3 N in combination with solvents (MeOH and DMF) to afford diol 6 in 65% yield. Subsequently, diol 6 was mesylated and transformed to (R)-(+)-Lipoic acid 7 by following the literature procedures. 
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Asymmetric Synthesis of (R)-(+)-Monobutyrin, a Novel Angiogenesis Factor via OsO 4 -Catalyzed Asymmetric Dihydroxylation (R)-Monobutyrin (1-butyrylglycerol, 9) is a naturally occurring lipid that stimulates angiogenesis. It is secreted by differentiating adipocites. It also stimulates one or more of the following endothelial cell function in vitro: protease production, motility, and proliferation. 6 fs24 The (R)-isomer is always bioactive. This section describes single step asymmetric synthesis of Monobutyrin via asymmetric dihydroxylation of allylbutyrate as shown in the Scheme 2. The allylbutyrate 8 was prepared from the esterification of butyric acid with allyl alcohol. Then it was subjected to OsO 4 -catalyzed asymmetric dihydroxylation in presence (DHQD) 2 -PHAL as chiral ligand using K 3 Fe(CN) 6 or NMO as a co-oxidant to give in optically active (R)-Monobutyrin 9 in 96% yield and 50% ee. CHAPTER 2 This chapter deals with the formation of chiral cyclic sulfates of 1,2-diols and their application to asymmetric synthesis of (S)-Xibenolol, an anti-inflammatory agent and (R)-Fepradinol, a b-adrenergic blocking agent. Cyclic sulfates 5 f0 have properties similar to epoxides but are more reactive than epoxides. However, in contrast to epoxides, reactions of cyclic sulfates with variety of nucleophiles are regiospecific leading to the formation of a single regioisomer. This chapter is divided into two sections. 
SECTION-I Chiral Cyclic Sulfate Mediated Asymmetric Synthesis of (S)-Xibenolol : A Versatile b-Adrenergic Blocker b-Adrenergic blocking agents (b-blockers) are cardiovascular drugs which exhibit three fundamental functions such as lowering the blood pressure (anti-hypertensive), return of the heart to rhythmic beating (anti-arrhythmics) and the general improvement of the heart muscle tone (cardiotonics). Xibenolol ((S)-[1-(dimethylethyl)amino]-3-(2,3-dimethylphenoxy)-2-propanol, 13) is a new b-adrenergic blocking agent clinically tested in its racemic form. It exhibits much more potent b-blocking activity than Propranolol. 7 Generally, it is accepted that most of the therapeutic actions of b-blocking agents, including anti-hypertensive and cardiovascular actions, are mediated mainly by the (S) and (-) isomer only. 8 In the view of this aspect we undertook the asymmetric synthesis of (S)-Xibenolol as shown in the Scheme 3. Our approach for synthesis of (S)-Xebenolol involves O-allylation of 2,3-dimethylphenol using allyl bromide to give allyl ether 10 in 97% yield, which was subjected to AD in presence (DHQD) 2 -PHAL to afford chiral diol 11 in 94% yield. The diol 11 was activated by transforming it into cyclic sulfate 12 in two steps in 81% overall yield, under the standard reaction conditions. 5 Regiospecific opening of cyclic sulfate 12 with tert-butyl amine afforded (S)-(-)-Xibenolol (13) in 90% yield and 67% ee. Figure (​http:​/​​/​www.csirexplorations.com​/​images_et​/​a75_figureNO2.jpg" \t "_blank​) 
SECTION-II Asymmetric Synthesis of Novel Non-steroidal Anti-inflammatory Agent, (R)-Fepradinol (R)-Fepradinol (1-phenyl-2-(a,a'-dimethylethanolamino)ethanol, 17) is a non-steroidal antiinflammetry drug. It possesses a potent inhibitory activity on the acute inflammation in rodents and that its anti-inflammatory activity does not seem to be related to an inhibitory effect on prostaglandin biosynthesis. 9 f0 Fepradinol also possesses structural similarities to that of other b-adrenergic blockers 10 f0 which account for the cardiovascular drugs. Our stratergy for asymmetric synthesis of (R)-Fepradinol involves styrene as precursor as shown in Scheme 4. It was subjected to AD in the presence of (DHQD) 2 -PHAL ligand to give chiral styrene diol 14 in 92% yield and 80%ee. The diol 14 was activated, by converting to cyclic sulfate 15 in two steps. However, cyclic sulfate 15 was found to be less stable and hence it was directly transformed to its epoxide 16 in two steps in 40% overall yield. The regiospecific opening of epoxide 16 with 2-amino-2-methylpropanol was achieved to give (R)-(-)-Fepradinol (17) in 55% yield. Figure (​http:​/​​/​www.csirexplorations.com​/​images_et​/​a75_figureNO3.jpg" \t "_blank​) 
CHAPTER 3 
This chapter deals with the asymmetric synthesis of (R)-Baclofen (22), a GABA B receptor agonist and acyclic nucleotide (24), anti-cholestermic agents, using Ru(II)-(S)-BINAP-catalyzed asymmetric hydrogenation and OsO 4 -catalyzed asymmetric dihydroxylation respectively. 
SECTION-I Synthesis of (R)-(-)-Baclofen, a Novel GABA B Receptor Agonist, via Ru(II)-BINAP Catalyzed Asymmetric Hydrogenation g-Aminobutryric acids (GABA) are important neurotransmitters and used in the treatment of epilepsy. Their deficiency is associated with diseases that exhibit neuromuscular dysfuntions such as epilepsy, Huntigton and Parkinsons' disease. 11 f0 (R)-Baclofen [g-amino-b-(p-chlorophenyl)butyric acid, 22] is one of the neurotransmitter, 12 f0 its asymmetric synthesis is presented in Scheme 5. Reformatsky reaction of 4-chloroacetophenone with ethylbromoacetate followed by dehydration gave a,b-unsaturated ester 18 in 78% overall yield. It was then subjected to allylic bromination with NBS to give bromo-derivative 19 in 92% yield. Subsequent displacement of bromide moiety in 19 by azido group afforded the key intermediate, azido-derivative 20 in 78%. It was subjected to Ru(II)-(S)-BINAP catalyzed asymmetric hydrogenation followed by Co-catalyzed reduction of azido-moiety with NaBH 4 led to the formation of chiral 3-arylpyrrolidine moiety 21. Hydrolysis of pyrrolidine moiety in 21 with dil. HCl gave optically active (R)-baclofen (22). Figure (​http:​/​​/​www.csirexplorations.com​/​images_et​/​a75_figureNO4.jpg" \t "_blank​) 
SECTION-II Synthesis of Acyclic Nucleoside Analog, (S)-2,3-Dihydroxypropyl-(9)-adenine, a Novel Anti-Viral Agent (S)-2,3-Dihydroxypropyl-(9)-adenine (DHPA, 25) is a acyclic nucleoside possessing wide range of antiviral activities. The (S)-DHPA inhibits the replication in vitro of several DNA and RNA viruses including vaccinia, herpes simplex, measles, and vesicular stomatitis. (S)-enantiomer has broad-spectrum activity and low acute toxicity. 13 f0 The asymmetric synthesis of (S)-DHPA from readily available allyl bromide is presented in Schemes 6. In order to synthesize 24, the strategy adopted was : (i) asymmetric dihydroxylation of allyl bromide in the presence of (DHQ) 2 -PHAL ligand to yield chiral bromodiol 23; (ii) N-alkylation of chiral bromodiol 23 with adenine. This chapter highlights the importance of transition metals such as Mn, Ru, Cu, etc. and their complexes as catalysts for some useful organic transformations. It is divided into three sections. 
SECTION-I: 
Chiral Manganese(III)-Salen as Catalyst in Asymmetric Bromination of Olefins with N-Bromosuccinimide Chiral Mn (III)-salen complex 25 (Jacobson's catalyst) is a well-known catalyst for asymmetric epoxidation, aziridination, hydroxylation, resolution of epoxide etc.. 14 Herein, we discovered yet another new application of this novel catalyst in asymmetric dibromination of olefins (26) using NBS as bromine source 15 (Scheme 7). The resulting chiral dibromides (27) can be transformed to chiral vic-diazides, diamines, diols, dithiols and aziridines, which are otherwise difficult to prepare, by direct addition to olefins. Thus asymmetric dibromination of olefins can provide a potential route to prepare variety of chiral dibromo-compounds which are useful intermediates in organic synthesis. 
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SECTION-II Catalytic C-H Oxidation of Alkyl Arenes to Aryl tert. Butyl Peroxide with TBHP over Ru(III)-Exchanged Montmorillonite K10 16 tabThe selective oxidation at the benzylic C-H bond of alkyl arenes constitutes a potential route for the functionalisation of alkyl arenes into oxygenated derivatives such as peroxides, alcohols, aldehydes, ketones and acids. The reaction selectivity to produce specific oxygenated derivatives such as peroxides is of crucial importance. We developed a mild and efficient catalytic method for the benzylic oxidation of alkyl arenes (28) to the corresponding tert. butyl aryl peroxides (29) using Ru III -exchanged Montmorillonite K10 as a reusable catalyst and aq. 70% tert. butyl hydroperoxide (TBHP) as oxidant. General method of peroxidation is given in Figure (​http:​/​​/​www.csirexplorations.com​/​images_et​/​a75_figureNO6.jpg" \t "_blank​)

